Novo Nordisk A/S vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Novo Nordisk A/S trades at $45.81 (market cap $207.85B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $31.06. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| NVO | TMF | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $44.14 |
52-Week Low | $35.29 | $30.59 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $31.43 with a modest 0.67% daily gain. Technical indicators show a bearish bias overall, with moving averages signaling caution, though oscillators are neutral. The ETF, which provides 3x leveraged exposure to long-duration U.S. Treasuries, faces significant volatility due to its daily leverage reset mechanism. Recent news highlights its high-risk nature, with one article noting a substantial decline from a $10,000 investment five years ago to approximately $1,527, underscoring the perils of long-term holding.
The outlook for TMF is highly speculative and tied to interest rate movements. While some see opportunity at perceived lows in the bond market, the consensus warns it is unsuitable for long-term investment. Primary risks include extreme volatility from daily leverage resets and adverse shifts in Treasury yields. It remains a tactical, short-term instrument for experienced traders, not a core portfolio holding.
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →